oral pyridostigmine and whatever degree of general support (mechanical respiratory ventilation, for example) is necessary until the condition clears. Infants with transient neonatal myasthenia gravis do not have an increased risk for the long-term or future development of myasthenia gravis.

**Should patients with congenital myasthenic syndromes avoid the same medications that may aggravate autoimmune myasthenia gravis?**

Yes. It is advisable to be cautious when starting newly prescribed or even some over-the-counter medications. Patients should check with their myasthenia physician prior to taking any new medications.

The MGFA mission is to facilitate the timely diagnosis and optimal care of individuals affected by myasthenia gravis and closely related disorders and to improve their lives through programs of patient services, public information, medical research, professional education, advocacy and patient care.

This publication is intended to provide the reader with general information to be used solely for educational purposes. As such, it does not address individual patient needs, and should not be used as a basis for decision making concerning diagnosis, care, or treatment of any condition. Instead, such decisions should be based upon the advice of a physician or health care professional who is directly familiar with the patient. The information contained in this publication reflects the views of the authors, but not necessarily those of the Myasthenia Gravis Foundation of America (MGFA). Any reference to a particular product, source, or use does not constitute an endorsement. MGFA, its agents, employees, Directors, Chapters, its Medical/Scientific Advisory Board, and its Nurses Advisory Board or their members make no warranty concerning the information contained in this publication. They specifically disclaim any warranty of merchantability, fitness for any particular purpose, or reliability regarding the information contained herein, and assume no responsibility for any damage or liability resulting from the use of such information.

© 2013 by Myasthenia Gravis Foundation of America, Inc.

Approved by the MGFA Medical/Scientific and Nurses Advisory Boards

Revised November 2013
Are there different types of congenital myasthenic syndromes?
Yes. Not all forms of congenital myasthenia are the same. A number of different types of congenital myasthenia have been identified with a variety of different structural and functional abnormalities of the neuromuscular junction. Patterns of inheritance, clinical symptoms, electrophysiology, and response to therapy vary depending on the type. Some of the subtypes that one may encounter include “familial infantile myasthenia,” a “congenital absence of acetylcholinesterase” presenting in infancy or childhood with generalized weakness and reduced muscle tone, “the slow channel syndrome,” which often follows an autosomal dominant pattern of inheritance with a variable age of onset and severity of symptoms, and a collection of disorders characterized by defective acetylcholine receptors.

Is there any reason to try to determine the exact type of congenital myasthenic syndrome?
A thorough diagnostic evaluation is worthwhile in patients with suspected congenital myasthenia because of the different types, and somewhat different treatment options. Patients with some subtypes may respond best to Mestinon® (pyridostigmine), while patients with other subtypes may respond best to other therapies (some types respond to ephedrine, some to 3, 4 DAP, quinidine or fluoxetine, as well as a variety of other drugs depending on the type of congenital myasthenia).

In general, what is the long-term prognosis for patients with congenital myasthenic syndromes?
Most patients remain fairly stable throughout their lifetime and tend not to have wide fluctuations of symptoms or function nor myasthenic crises. Overall, patients tend to stay about the same on a long-term basis.

What is the difference between congenital myasthenia and transient neonatal myasthenia?
Transient neonatal myasthenia occurs in 10-15% of babies born to mothers with autoimmune myasthenia gravis. Within the first few days after delivery, the infant has a weak cry or suck, appears generally weak, and on occasion, requires mechanical ventilation. Maternal antibodies that cross the placenta late in pregnancy cause transient neonatal myasthenia. As these maternal antibodies are replaced by the infant’s own antibodies, the symptoms gradually disappear, usually within a few weeks, and the baby is normal thereafter. Infants with severe weakness from transient neonatal myasthenia may be treated with...